Get the Daily Brief
Latest Biotech News
TIGIT Antibody Failures Spotlight Challenges in Immuno-Oncology Investment
The once-hyped immuno-oncology target TIGIT has encountered significant setbacks, with leading drugs like BeOne Medicines’ ociperlimab and GSK’s belrestotug discontinued after disappointing...
Thermo Fisher Considers Diagnostics Divestment Amid Market Pressures
Thermo Fisher Scientific’s shares dropped over 1% following reports of exploring a sale of part of its diagnostics unit, including its microbiology business, with a potential valuation of around...
Immunai Partners with Parker Institute to Enhance AI Immune Models Using Single-Cell Data
Immunai has entered a partnership with the Parker Institute for Cancer Immunotherapy to generate an extensive single-cell gene expression dataset from a cancer patient cohort receiving immune...
City of Hope Reveals Tumor ecDNA Maps, Enabling Personalized Brain Cancer Insights
City of Hope scientists have co-led research that characterizes extrachromosomal DNA (ecDNA) in brain tumors, linking these structures to oncogene activity and hypoxic tumor microenvironments. The...
BioNTech Acquires CureVac in $1.25B Stock Deal Strengthening Oncology Push
BioNTech has agreed to acquire mRNA vaccine and cancer immunotherapy developer CureVac in an all-stock transaction valued at approximately $1.25 billion. The deal emphasizes gaining CureVac’s...
AI Pre-Training on Retinal Waves Enhances Neural Network Motion Prediction
Technical University of Munich researchers demonstrated that artificial neural networks trained with biological data—specifically spontaneous retinal waves observed in early visual system...
BioNTech Buys CureVac in $1.25 Billion mRNA Deal
BioNTech announced the $1.25 billion all-stock acquisition of CureVac, a German mRNA vaccine developer, aiming to bolster its cancer immunotherapy portfolio and resolve existing patent disputes....
FDA Broadens Moderna RSV Vaccine Eligibility
The FDA approved Moderna's RSV vaccine mRESVIA for expanded use in at-risk adults aged 18 to 59, enhancing preventive options against respiratory syncytial virus infections. Building on mRNA...
ADC Therapeutics Shutters UK R&D, Cuts 30% Workforce
After clinical setbacks and ceasing development of its only clinical-stage candidate, ADC Therapeutics announced closure of its UK R&D facility and a 30% workforce reduction. Early-stage program...
BioNTech Expands Oncology Footprint with $1.25B CureVac Deal
BioNTech, known for its mRNA COVID-19 vaccine developed with Pfizer, announced the acquisition of German mRNA developer CureVac in an all-stock transaction valued at approximately $1.25 billion....
Advanced Gene Therapy Manufacturing Collaboration Launched
MaxCyte and Ori Biotech joined forces to optimize manufacturing of autologous cellular therapies by integrating MaxCyte’s ExPERT and flow electroporation technologies with Ori’s IRO platform. This...
Brain–Computer Interface Advances Enable Instantaneous Speech
Researchers developed a brain-to-voice neuroprosthesis capable of decoding neural activity in real time to synthesize emotive speech in a man with ALS, via 256 microelectrodes implanted in the...
AI-Enabled Broad-Spectrum Coronavirus Drug Developed
At Harvard’s Wyss Institute, a multidisciplinary team used AI-enabled dynamic molecular modeling, inspired by film industry animation techniques, to repurpose and optimize antiviral agents with...
Rising T1DE Alliance Expands Data-Driven Diabetes Care Model
The Rising T1DE Alliance added Ann & Robert H. Lurie Children’s Hospital of Chicago, supported by a recent $5.1 million Helmsley Charitable Trust grant, aiming to disseminate scalable type 1...
Industry Restructuring: ADC Therapeutics Ends Programs, Cuts Staff
Swiss biopharma ADC Therapeutics announced the closure of its UK R&D site and layoffs trimming its workforce by 30%, following the discontinuation of its only clinical-stage candidate for B-cell...
Exercise-Induced Protective Responses in Alzheimer’s Mouse Model
Using single-nucleus RNA sequencing, researchers detailed cell-specific molecular responses to exercise in the hippocampal dentate gyrus of an Alzheimer’s disease mouse model. Exercise restored...
FDA Expands Moderna’s RSV Vaccine Use in Adults
The FDA approved Moderna’s mRESVIA RSV vaccine for a broader adult at-risk population aged 18 to 59, following recent COVID-19 vaccine approvals. This expansion aims to provide preventive options...
Novel AML Treatment Combination Shows High Remission Rates
An early-phase trial at UNC Lineberger demonstrated that adding the menin inhibitor revumenib to standard azacitidine and venetoclax therapy yields high complete remission rates in AML patients...
Quantum Network Advances Redefining Precision Timing
A multi-national team achieved the most extensive coordinated comparison of optical atomic clocks over thousands of kilometers, operating ten different clock systems simultaneously. This work...
BioNTech Seals $1.25B Deal to Acquire CureVac’s mRNA Assets
BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating leadership in mRNA technology and expanding cancer immunotherapy capabilities. The deal, which offers...